👤 Hui Wu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
1732
Articles
1210
Name variants
Also published as: Aimin Wu, Alexander T H Wu, Alice Ying-Jung Wu, An Guo Wu, An-Chih Wu, An-Dong Wu, An-Hua Wu, An-Li Wu, An-Xin Wu, Andong Wu, Anguo Wu, Anke Wu, Anna H Wu, Anping Wu, Anshi Wu, Anyi Wu, Anyue Wu, Anzhou Wu, B Wu, Baiyan Wu, Baochuan Wu, Baojian Wu, Baojin Wu, Baoqin Wu, Beier Wu, Beili Wu, Ben J Wu, Bian Wu, Biaoliang Wu, Bifeng Wu, Bill X Wu, Bin Wu, Binbin Wu, Bing Wu, Bing-Bing Wu, Bingjie Wu, Binxin Wu, Biwei Wu, Bo Wu, Boquan Wu, Buling Wu, C Wu, C-H Wu, Cai-Qin Wu, Caihong Wu, Caisheng Wu, Caiwen Wu, Catherine A Wu, Chang-Jiun Wu, Changchen Wu, Changjie Wu, Changjing Wu, Changwei Wu, Changxin Wu, Changyu Wu, Chao Wu, Chao-Liang Wu, Chaoling Wu, Chaowei Wu, Chen Wu, Chen-Lu Wu, Cheng Wu, Cheng-Chun Wu, Cheng-Hsin Wu, Cheng-Hua Wu, Cheng-Jang Wu, Cheng-Jun Wu, Cheng-Yang Wu, Chengbiao Wu, Chengqian Wu, Chengrong Wu, Chengwei Wu, Chengxi Wu, Chengyu Wu, Chenyang Wu, Chew-Wun Wu, Chi-Chung Wu, Chi-Hao Wu, Chi-Jen Wu, Chia-Chang Wu, Chia-Chen Wu, Chia-Ling Wu, Chia-Lung Wu, Chia-Zhen Wu, Chiao-En Wu, Chieh-Jen Wu, Chieh-Lin Stanley Wu, Chien-Sheng Wu, Chien-Ting Wu, Chih-Ching Wu, Chih-Chung Wu, Chih-Hsing Wu, Ching-Yi Wu, Cho-Kai Wu, Chong Wu, Chongming Wu, Choufei Wu, Chris Y Wu, Chuan-Ling Wu, Chuang Wu, Chuanhong Wu, Chun Wu, Chun-Chieh Wu, Chun-Hua Wu, Chunfu Wu, Chung-Yi Wu, Chunru Wu, Chunshuai Wu, Chunyan Wu, Colin Chih-Chien Wu, Colin O Wu, Cong Wu, Congying Wu, Constance Wu, Cuiling Wu, Cuiyan Wu, D I Wu, D P Wu, D Wu, Da-Hua Wu, Dai-Chao Wu, Dan Wu, Dan-Chun Wu, Dandan Wu, Danhong Wu, Danni Wu, Daoyuan Wu, Dapeng Wu, Daqing Wu, Daren Wu, David Wu, Daxian Wu, De Wu, De-Fu Wu, Deguang Wu, Dengying Wu, Depei Wu, Depeng Wu, Deqing Wu, Di Wu, Diana H Wu, Diana Wu, Dianqing Wu, Ding Lan Wu, Dirong Wu, Dishan Wu, Disheng Wu, Do-Bo Wu, Dong Wu, Dong-Bo Wu, Dong-Fang Wu, Dong-Feng Wu, Donglin Wu, Dongmei Wu, Dongping Wu, Dongsheng Wu, Dongyan Wu, Dongzhe Wu, Douglas C Wu, Duojiao Wu, Ed Xuekui Wu, Eugenia Wu, Fan Wu, Fanchang Wu, Fang Wu, Fang-Tzu Wu, Fangge Wu, Fanggeng Wu, Fei Wu, Fei-Fei Wu, Feifei Wu, Fenfang Wu, Feng Wu, Fengming Wu, Fengying Wu, Fong-Li Wu, G Wu, G X Wu, Gaige Wu, Gang Wu, Gaojun Wu, Ge-ru Wu, Gen Sheng Wu, Gen Wu, Geng-ze Wu, Geping Wu, Geting Wu, Geyan Wu, Grace F Wu, Guang-Bo Wu, Guang-Liang Wu, Guang-Long Wu, Guanggeng Wu, Guangjie Wu, Guangming Wu, Guangrun Wu, Guangsen Wu, Guangxi Wu, Guangxian Wu, Guangyan Wu, Guangzhen Wu, Guanhui Wu, Guanming Wu, Guanrong Wu, Guanxian Wu, Guanyi Wu, Guanzhao Wu, Guanzhong Wu, Gui-Qin Wu, Guifen Wu, Guifu Wu, Guihua Wu, Guiping Wu, Guixin Wu, Guizhen Wu, Guo-Chao Wu, Guofeng Wu, Guohao Wu, Guojun Wu, Guoli Wu, Guoping Wu, Guoqing Wu, Guorong Wu, Guoyao Wu, H J Wu, H Wu, Hai-Ping Wu, Hai-Yan Wu, Hai-Yin Wu, Haibin Wu, Haidong Wu, Haihu Wu, Haijiang Wu, Haijing Wu, Hailong Wu, Haiping Wu, Haishan Wu, Haisu Wu, Haiwei Wu, Haixia Wu, Haiyan Wu, Haiying Wu, Haiyun Wu, Han Wu, Han-Jie Wu, Hang Wu, Hanyu Wu, Hao Wu, Hao-Tian Wu, Haoan Wu, Haodi Wu, Haomin Wu, Haoming Wu, Haoxuan Wu, Haoze Wu, He Wu, Hei Man Wu, Hei-Man Wu, Hengyu Wu, Hon-Yen Wu, Hong Wu, Hong-Fu Wu, Hong-Mei Wu, Hongfei Wu, Hongfu Wu, Hongke Wu, Hongliang Wu, Honglin Wu, Hongmei Wu, Hongting Wu, Hongxi Wu, Hongxian Wu, Hongyan Wu, Hongyu Wu, Hsan-Au Wu, Hsi-Chin Wu, Hsien-Ming Wu, Hsing-Chieh Wu, Hsiu-Chuan Wu, Hsueh-Erh Wu, Hua Wu, Hua-Yu Wu, Huan Wu, Huanghui Wu, Huanlin Wu, Huanwen Wu, Huating Wu, Huazhang Wu, Huazhen Wu, Hui-Chen Wu, Hui-Hui Wu, Hui-Mei Wu, Hui-Xuan Wu, Huijian Wu, Huijuan Wu, Huini Wu, Huisheng Wu, Huiwen Wu, Hung-Tsung Wu, I H Wu, Irene X Y Wu, J W Wu, J Wu, J Y Wu, J-Z Wu, Jamie L Y Wu, Jason H Y Wu, Jason Wu, Jemma X Wu, Jer-Yuan Wu, Jer-Yuarn Wu, Jerry Wu, Ji-Zhou Wu, Jia Wu, Jia-En Wu, Jia-Hui Wu, Jia-Jun Wu, Jia-Qi Wu, Jia-Wei Wu, Jiahang Wu, Jiahao Wu, Jiahui Wu, Jiajin Wu, Jiajing Wu, Jiake Wu, Jiamei Wu, Jian Hui Wu, Jian Wu, Jian-Lin Wu, Jian-Qiu Wu, Jian-Yi Wu, Jiang Wu, Jiang-Bo Wu, Jiang-Nan Wu, Jiangdong Wu, Jianguang Wu, Jiangyue Wu, Jianhui Wu, Jianing Wu, Jianjin Wu, Jianjun Wu, Jianli Wu, Jianliang Wu, Jianmin Wu, Jianming Wu, Jianping Wu, Jianqiang Wu, Jianrong Wu, Jianwu Wu, Jianxin Wu, Jianxiong Wu, Jianyi Wu, Jianying Wu, Jianzhang Wu, Jianzhi Wu, Jianzhong Wu, Jiao Wu, Jiapei Wu, Jiaqi Wu, Jiarui Wu, Jiawei Wu, Jiaxi Wu, Jiaxuan Wu, Jiayi Wu, Jiayu Wu, Jiayuan Wu, Jie Wu, JieQian Wu, Jiexi Wu, Jihui Wu, Jin Wu, Jin'en Wu, Jin-Shang Wu, Jin-Zhen Wu, Jin-hua Wu, Jincheng Wu, Jinfeng Wu, Jing Wu, Jing-Fang Wu, Jing-Wen Wu, Jinghong Wu, Jingjing Wu, Jingtao Wu, Jingwan Wu, Jingyi Wu, Jingyue Wu, Jingyun Wu, Jinhua Wu, Jinhui Wu, Jinjie Wu, Jinjun Wu, Jinmei Wu, Jinqiao Wu, Jinyu Wu, Jinze Wu, Jiong Wu, Jiu-Lin Wu, Joseph C Wu, Joshua L Wu, Ju Wu, Juan Wu, Juanjuan Wu, Juanli Wu, Jugang Wu, Julian Wu, Jun Wu, Jundong Wu, Junduo Wu, June K Wu, June-Hsieh Wu, Junfang Wu, Junfei Wu, Junfeng Wu, Junhua Wu, Junjie Wu, Junjing Wu, Junlong Wu, Junqi Wu, Junqing Wu, Junshu Wu, Junyi Wu, Junyong Wu, Junzheng Wu, Junzhu Wu, Justin C Y Wu, Justin Che-Yuen Wu, K D Wu, K S Wu, Kai-Hong Wu, Kai-Yue Wu, Kailang Wu, Kaili Wu, Kan Wu, Kay L H Wu, Ke Wu, Kebang Wu, Keija Wu, Kejia Wu, Kerui Wu, Kevin Zl Wu, Kuan-Li Wu, Kuen-Phon Wu, Kui Wu, Kuixian Wu, Kun Wu, Kun-Rong Wu, Kunfang Wu, Kunling Wu, Kunsheng Wu, L Wu, L-F Wu, Lai Man Natalie Wu, Lan Wu, Lanlan Wu, Lanxiang Wu, Lecheng Wu, Lei Wu, Leilei Wu, Lesley Wu, Leslie Wu, Li Wu, Li-Hsien Wu, Li-Jun Wu, Li-Ling Wu, Li-Na Wu, Li-Peng Wu, Liang Wu, Liang-Huan Wu, Liangyan Wu, Lianqian Wu, Lichao Wu, Lidi Wu, Lifang Wu, Lifeng Wu, Lihong Wu, Lijie Wu, Lijuan Wu, Lijun Wu, Lili Wu, Limei Wu, Limeng Wu, Lin Wu, Lin-Han Wu, Ling Wu, Ling-Fei Wu, Ling-Ying Wu, Ling-qian Wu, Lingling Wu, Lingqian Wu, Lingxi Wu, Lingxiang Wu, Lingyan Wu, Lingyun Wu, Lingzhi Wu, Linhong Wu, Linmei Wu, Lintao Wu, Linxiang Wu, Linyu Wu, Linzhen Wu, Linzhi Wu, Lipeng Wu, Liping Wu, Liqiang Wu, Liqun Wu, Liren Wu, Lisha Wu, Liting Wu, Litong Wu, Liufeng Wu, Liuting Wu, Liuxin Wu, Liuying Wu, Lixing Wu, Liyan Wu, Liyang Wu, Lizhen Wu, Lizi Wu, Long-Jun Wu, Longting Wu, Lorna Wu, Lulu Wu, Lun Wu, Lun-Gang Wu, Luyan Wu, M Wu, Ma Wu, Man Wu, Man-Jing Wu, Maoqing Wu, Mark N Wu, Matthew A Wu, Maureen Wu, Mei Wu, Mei-Hwan Wu, Mei-Na Wu, Meili Wu, Meina Wu, Meini Wu, Meiqi Wu, Meiqin Wu, Meng Wu, Meng-Chao Wu, Meng-Han Wu, Meng-Hsun Wu, Meng-Ling Wu, Meng-Na Wu, Mengbo Wu, Mengchao Wu, Mengjuan Wu, Mengjun Wu, Mengna Wu, Mengqiu Wu, Mengxue Wu, Mengying Wu, Mengyuan Wu, Mian Wu, Michael C Wu, Min Wu, Min-Jiao Wu, Ming J Wu, Ming Wu, Ming-Der Wu, Ming-Jiuan Wu, Ming-Shiang Wu, Ming-Sian Wu, Ming-Tao Wu, Ming-Yue Wu, Mingfu Wu, Minghua Wu, Mingjie Wu, Mingjun Wu, Mingming Wu, Mingxing Wu, Mingxuan Wu, Minna Wu, Minqing Wu, Minyao Wu, Moxin Wu, Muzhou Wu, N Wu, Na Wu, Na-Qiong Wu, Nan Wu, Nana Wu, Naqiong Wu, Ning Wu, Nini Wu, Niting Wu, P L Wu, Panyun Wu, Paul W Wu, Pei Wu, Pei-Ei Wu, Pei-Ting Wu, Pei-Wen Wu, Pei-Yu Wu, Peih-Shan Wu, Peiyao Wu, Peiyi Wu, Peng Wu, Peng-Fei Wu, Pengfei Wu, Pengjie Wu, Pengning Wu, Pensee Wu, Pin Wu, Ping Wu, Ping-Hsun Wu, Pinglian Wu, Pingxian Wu, Po-Chang Wu, Qi Wu, Qi-Biao Wu, Qi-Fang Wu, Qi-Jun Wu, Qi-Nian Wu, Qi-Yong Wu, Qi-Zhu Wu, Qian Wu, Qian-Yan Wu, Qiang Wu, Qianhu Wu, Qianqian Wu, Qianwen Wu, Qiao Wu, Qiaowei Wu, Qibiao Wu, Qibing Wu, Qihan Wu, Qijing Wu, Qin Wu, Qinan Wu, Qinfeng Wu, Qing Wu, Qing-Qian Wu, Qing-Wu Wu, Qinghua Wu, Qinglan Wu, Qinglin Wu, Qingping Wu, Qingshi Wu, Qinyi Wu, Qiong Wu, Qiqing Wu, Qitian Wu, Qiu Wu, Qiu-Li Wu, Qiuchen Wu, Qiuhong Wu, Qiuji Wu, Qiulian Wu, Qiuliang Wu, Qiuxia Wu, Qiuya Wu, Quanhui Wu, Qunzheng Wu, R M Wu, R Ryanne Wu, R Wu, R-J Wu, Ran Wu, Ray-Chin Wu, Re-Wen Wu, Ren Wu, Ren-Chin Wu, Renhai Wu, Renlv Wu, Renrong Wu, Riping Wu, Rong Wu, Ronghua Wu, Rongjie Wu, Rongling Wu, Rongrong Wu, Ru-Zi Wu, Rui Wu, Ruihong Wu, Ruize Wu, Run Wu, Runda Wu, Runpei Wu, Ruohao Wu, Ruolan Wu, Ruonan Wu, Ruying Wu, S F Wu, S J Wu, S L Wu, S M Wu, S Wu, S-F Wu, Sai Wu, Samuel M Wu, San-pin Wu, Sarah Wu, Sean M Wu, Selena Meiyun Wu, Selwin K Wu, Semon Wu, Sen-Chao Wu, Senquan Wu, Sensen Wu, Shao-Guo Wu, Shao-Ming Wu, Shaofei Wu, Shaohuan Wu, Shaojun Wu, Shaoping Wu, Shaoxuan Wu, Shaoyu Wu, Shaoze Wu, Sheng-Li Wu, Shengde Wu, Shengming Wu, Shengnan Wu, Shengru Wu, Shengxi Wu, Shenhao Wu, Shenyue Wu, Shi-Xin Wu, Shibo Wu, Shih-Ying Wu, Shihao Wu, Shin-Long Wu, Shinan Wu, Shiqi Wu, Shiwen Wu, Shixin Wu, Shiya Wu, Shiyang Wu, Shu Wu, Shuai Wu, Shuang Wu, Shufang Wu, Shugeng Wu, Shuihua Wu, Shuisheng Wu, Shujuan Wu, Shunan Wu, Shuo Wu, Shusheng Wu, Shuting Wu, Shuyan Wu, Shuyi Wu, Shuying Wu, Shwu-Yuan Wu, Shyh-Jong Wu, Si-Jia Wu, Sichen Wu, Sihan Wu, Sihui Wu, Sijie Wu, Sijun Wu, Siming Wu, Siqi Wu, Siyi Wu, Siying Wu, Siyu Wu, Song Wu, Songfen Wu, Su Wu, Su-Hui Wu, Suhua Wu, Sunyi Wu, Szu-Hsien Wu, T Wu, Tangchun Wu, Tao Wu, Teng Wu, Terence Wu, Thomas D Wu, Tian Wu, Tiange Wu, Tianhao Wu, Tianqi Wu, Tiantian Wu, Tianwen Wu, Tianzhi Wu, Ting-Feng Wu, Ting-Ting Wu, Tingchun Wu, Tingqin Wu, Tingting Wu, Tong Wu, Tracy Wu, Tsai-Kun Wu, Tsung-Jui Wu, Tsung-Teh Wu, Tung-Ho Wu, Tzu-Chun Wu, V C Wu, W J Wu, W Wu, Wan-Fu Wu, Wanxia Wu, Wei Wu, Wei-Chi Wu, Wei-Ping Wu, Wei-Xun Wu, Wei-Yin Wu, Weibin Wu, Weida Wu, Weidong Wu, Weihua Wu, Weijie Wu, Weijun Wu, Weiwei Wu, Weizhen Wu, Wen Wu, Wen-Chieh Wu, Wen-Hui Wu, Wen-Jeng Wu, Wen-Juan Wu, Wen-Ling Wu, Wen-Qiang Wu, Wen-Sheng Wu, Wen-Shu Wu, Wenda Wu, Wendy Wu, Wenhui Wu, Wenjie Wu, Wenjing Wu, Wenjuan Wu, Wenjun Wu, Wenlin Wu, Wenqi Wu, Wenqian Wu, Wenqiang Wu, Wenwen Wu, Wenxian Wu, Wenxue Wu, Wenyi Wu, Wenyong Wu, Wenyu Wu, Wenze Wu, William K K Wu, William Ka Kei Wu, Wu-Tian Wu, Wudelehu Wu, Wujun Wu, Wutain Wu, Wutian Wu, Xi Wu, Xi-Chen Wu, Xi-Ze Wu, Xia Wu, Xiahui Wu, Xian-Run Wu, Xianan Wu, Xianfeng Wu, Xiangping Wu, Xiangsheng Wu, Xiangwei Wu, Xiangxin Wu, Xianpei Wu, Xiao Wu, Xiao-Cheng Wu, Xiao-Hui Wu, Xiao-Jin Wu, Xiao-Jun Wu, Xiao-Yan Wu, Xiao-Yang Wu, Xiao-Ye Wu, Xiao-Yuan Wu, Xiaobin Wu, Xiaobing Wu, Xiaodi Wu, Xiaodong Wu, Xiaofan Wu, Xiaofeng Wu, Xiaofu Wu, Xiaohong Wu, Xiaohui Wu, Xiaojiang Wu, Xiaojie Wu, Xiaojin Wu, Xiaojing Wu, Xiaojun Wu, Xiaokang Wu, Xiaoke Wu, Xiaolang Wu, Xiaoli Wu, Xiaoliang Wu, Xiaolin Wu, Xiaoling Wu, Xiaolong Wu, Xiaoman Wu, Xiaomei Wu, Xiaomeng Wu, Xiaomin Wu, Xiaoming Wu, Xiaoping Wu, Xiaoqian Wu, Xiaoqing Wu, Xiaoqiong Wu, Xiaorong Wu, Xiaoting Wu, Xiaotong Wu, Xiaoxing Wu, Xiaoyang Wu, Xiaoying Wu, Xiaoyong Wu, Xiaoyun Wu, Xiayin Wu, Xiexing Wu, Xifeng Wu, Xihai Wu, Xilin Wu, Xilong Wu, Ximei Wu, Xin Wu, Xin-Xi Wu, Xinchun Wu, Xing Wu, Xing-De Wu, Xing-Ping Wu, Xingdong Wu, Xinghua Wu, Xingjie Wu, Xinglong Wu, Xingwei Wu, Xinhe Wu, Xinjing Wu, Xinlei Wu, Xinmiao Wu, Xinran Wu, Xinrui Wu, Xinyan Wu, Xinyang Wu, Xinyi Wu, Xinyin Wu, Xiping Wu, Xiru Wu, Xiu-Zhi Wu, Xiuhua Wu, Xiushan Wu, Xiwei Wu, Xu Wu, Xuan Wu, Xuanqin Wu, Xuanshuang Wu, Xudong Wu, Xue Wu, Xue-Mei Wu, Xue-Yan Wu, Xuefen Wu, Xuefeng Wu, Xueji Wu, Xuekun Wu, Xueling Wu, Xuemei Wu, Xueqian Wu, Xueqing Wu, Xueyan Wu, Xueyao Wu, Xueying Wu, Xueyuan Wu, Xuhan Wu, Xunwei Wu, Xuxian Wu, Y H Wu, Y Q Wu, Y Wu, Y Y Wu, Y-W Wu, Ya Wu, Yadi Wu, Yafei Wu, Yajie Wu, Yalan Wu, Yali Wu, Yan Wu, Yan Yan Wu, Yan-Hua Wu, Yan-Jun Wu, Yan-ling Wu, Yanan Wu, Yanchuan Wu, Yanchun Wu, Yandi Wu, Yang Wu, Yangfeng Wu, Yangna Wu, Yangyu Wu, Yanhong Wu, Yanhua Wu, Yanhui Wu, Yanjing Wu, Yanli Wu, Yanqiong Wu, Yanran Wu, Yansheng Wu, Yanting Wu, Yanxiang Wu, Yanyan Wu, Yanzhi Wu, Yao Wu, Yaohong Wu, Yaohua Wu, Yaojiong Wu, Yaoxing Wu, Yaping Wu, Yaqin Wu, Yaru Wu, Yawei Wu, Yawen Wu, Ye Wu, Yen-Wen Wu, Yetong Wu, Yexiang Wu, Yi Wu, Yi-Cheng Wu, Yi-Fang Wu, Yi-Hua Wu, Yi-Long Wu, Yi-Mi Wu, Yi-Ming Wu, Yi-No Wu, Yi-Syuan Wu, Yi-Xia Wu, Yi-Ying Wu, Yibo Wu, Yichen Wu, Yicheng Wu, Yifan Wu, Yifeng Wu, Yih-Jer Wu, Yih-Ru Wu, Yihan Wu, Yihang Wu, Yihe Wu, Yihua Wu, Yihui Wu, Yijian Wu, Yili Wu, Yillin Wu, Yilong Wu, Yin Wu, Yinan Wu, Ying Wu, Ying-Ting Wu, Ying-Ying Wu, Yingbiao Wu, Yinghao Wu, Yingning Wu, Yingxia Wu, Yingying Wu, Yingzhi Wu, Yipeng Wu, Yiping Wu, Yiqun Wu, Yiran Wu, Yiting Wu, Yiwen Wu, Yixia Wu, Yixuan Wu, Yiyang Wu, Yiyi Wu, Yizhou Wu, Yong Wu, Yong-Hao Wu, Yong-Hong Wu, Yongfa Wu, Yongfei Wu, Yonghui Wu, Yongjiang Wu, Yongmei Wu, Yongqi Wu, Yongqun Wu, You Wu, Yu Wu, Yu'e Wu, Yu-Chih Wu, Yu-E Wu, Yu-Hsuan Wu, Yu-Ke Wu, Yu-Ling Wu, Yu-Ting Wu, Yu-Yuan Wu, Yuan Kai Wu, Yuan Wu, Yuan-de Wu, Yuanbing Wu, Yuanhao Wu, Yuanming Wu, Yuanshun Wu, Yuanyuan Wu, Yuanzhao Wu, Yucan Wu, Yuchen Wu, Yudan Wu, Yue Wu, Yueheng Wu, Yueling Wu, Yueming Wu, Yuen-Jung Wu, Yuesheng Wu, Yuetong Wu, Yuexiu Wu, Yuguang Philip Wu, Yuh-Lin Wu, Yuhong Wu, Yujie Wu, Yujuan Wu, Yukang Wu, Yulian Wu, Yuliang Wu, Yulin Wu, Yumei Wu, Yumin Wu, Yuming Wu, Yun Wu, Yun-Wen Wu, Yuna Wu, Yung-Fu Wu, Yunhua Wu, Yunpeng Wu, Yupeng Wu, Yuqin Wu, Yurong Wu, Yushun Wu, Yuting Wu, Yutong Wu, Yuwei Wu, Yuxian Wu, Yuxiang Wu, Yuxin Wu, Yuyi Wu, Yuyu Wu, Z Wu, Zaihao Wu, Ze Wu, Zelai Wu, Zeng-An Wu, Zhangjie Wu, Zhao-Bo Wu, Zhao-Yang Wu, Zhaofei Wu, Zhaoxia Wu, Zhaoyang Wu, Zhaoyi Wu, Zhaoyuan Wu, Zhe Wu, Zheming Wu, Zhen Wu, Zhen-Qi Wu, Zhen-Yang Wu, Zhenfang Wu, Zhenfeng Wu, Zheng Wu, Zhengcan Wu, Zhengfeng Wu, Zhengliang L Wu, Zhengsheng Wu, Zhenguo Wu, Zhengyu Wu, Zhengzhi Wu, Zhenling Wu, Zhenlong Wu, Zhentian Wu, Zhenyan Wu, Zhenyong Wu, Zhenzhen Wu, Zhenzhou Wu, Zhi-Hong Wu, Zhi-Wei Wu, Zhi-Yong Wu, Zhibing Wu, Zhichong Wu, Zhidan Wu, Zhihao Wu, Zhikang Wu, Zhimin Wu, Zhipeng Wu, Zhiping Wu, Zhiqiang Wu, Zhixiang Wu, Zhiye Wu, Zhong Wu, Zhong-Jun Wu, Zhong-Yan Wu, Zhongchan Wu, Zhonghui Wu, Zhongjun Wu, Zhongluan Wu, Zhongqiu Wu, Zhongren Wu, Zhongwei Wu, Zhongyang Wu, Zhou Wu, Zhou-Ming Wu, Zhourui Wu, Zhuanbin Wu, Zhuokai Wu, Zhuoze Wu, Zhuzhu Wu, Zijun Wu, Ziliang Wu, Zilong Wu, Zimu Wu, Zixiang Wu, Zixuan Wu, Zoe Wu, Zong-Jia Wu, Zongfu Wu, Zongheng Wu, Zujun Wu, Zuping Wu
articles
Xin Lei, Tao Lang, Shan Gao +2 more · 2026 · Clinical genetics · Blackwell Publishing · added 2026-04-24
The mechanisms by which the autosomal dominant disorder tuberous sclerosis complex (TSC) results in liver fibrosis remain poorly understood. KDM6A, a histone demethylase, has been implicated in the pa Show more
The mechanisms by which the autosomal dominant disorder tuberous sclerosis complex (TSC) results in liver fibrosis remain poorly understood. KDM6A, a histone demethylase, has been implicated in the pathogenesis of fibrosis in multiple tissues. This study aimed to elucidate the molecular mechanism by which KDM6A contributed to TSC-associated fibrosis. We observed fibrogenesis, epithelial-mesenchymal transition (EMT) induction and upregulation of Kdm6a in vivo and in vitro upon Tsc1 or Tsc2 deficiency. Knockdown of Kdm6a attenuated both fibrosis and EMT phenotypes. Mechanistically, Kdm6a depletion reduced phosphorylation of ERK1/2 and downregulated Snai1 expression. Activation of the MAPK/ERK pathway with PMA restored EMT-related protein expression, confirming the functional involvement of this signaling axis. Furthermore, Tsc1 or Tsc2 deficiency promoted Kdm6a expression via the mTORC1 pathway, while Kdm6a knockdown conversely suppressed mTORC1 activity by reducing mTOR protein expression, suggesting a positive feedback loop between Kdm6a expression and mTORC1. These findings indicate that Kdm6a promotes fibrosis in TSC through the activation of the MAPK/ERK/SNAI1 signaling pathway. Moreover, the combination of mTORC1 and KDM6A inhibitors results in marked regression of fibrosis and liver lesions in TSC models, unveiling a potential treatment for TSC patients with inadequate response to mTORC1 inhibitors. Show less
no PDF DOI: 10.1111/cge.70136
SNAI1
Wenke Wang, Wenjie Wu, Mingjun Hao +5 more · 2026 · Cell death & disease · Nature · added 2026-04-24
Granulosa cell (GC) apoptosis is intrinsically linked to the ovarian dysfunction of polycystic ovary syndrome (PCOS). Although oxidative stress and apoptosis in GCs have been detected in PCOS patients Show more
Granulosa cell (GC) apoptosis is intrinsically linked to the ovarian dysfunction of polycystic ovary syndrome (PCOS). Although oxidative stress and apoptosis in GCs have been detected in PCOS patients, how reactive oxygen species (ROS) links to GC apoptosis in PCOS remains to be further elucidated. Here, by integrating public single-cell RNA-seq data with clinical GC sample validation, we found that the expression of the E3 ubiquitin ligase WWP2 was significantly reduced, whereas its role in PCOS has not been previously reported. Notably, we first demonstrated that WWP2 overexpression can effectively antagonize mitochondrial apoptosis and ROS in KGNs. Mechanistically, oxidative stress weakened the interaction between WWP2 and BAK and reduced WWP2 expression, thereby suppressing BAK ubiquitination at Lys113. This inhibition impaired proteasomal degradation and consequently increased BAK protein levels. Consistently, disrupting BAK ubiquitination (BAK-K113R mutant) or knocking down WWP2 facilitated KGN apoptosis, and genetic ablation of Wwp2 in PCOS mice further aggravated GC apoptosis and hormonal disturbances. This study elucidates the molecular mechanism by which oxidative stress modulates GC mitochondrial apoptosis through WWP2-mediated BAK ubiquitination, and establishes WWP2 as a potential therapeutic target for PCOS. Show less
no PDF DOI: 10.1038/s41419-026-08500-y
WWP2
Mengqiu Wu, Mengqiu Miao, Yuting Li +12 more · 2026 · Molecular therapy : the journal of the American Society of Gene Therapy · Elsevier · added 2026-04-24
Defects in mitochondrial energy metabolism in injured tubular epithelial cells (TECs) are a well-recognized hallmark of kidney injury pathogenesis; however, the key target leading to this defect durin Show more
Defects in mitochondrial energy metabolism in injured tubular epithelial cells (TECs) are a well-recognized hallmark of kidney injury pathogenesis; however, the key target leading to this defect during the acute kidney injury (AKI)-to-chronic kidney disease (CKD) transition remains elusive. Here, we found that during the AKI-to-CKD transition, the increased WW domain containing E3 ubiquitin protein ligase 2 (WWP2) was shuttled to the mitochondria and disabled TEC mitochondrial energy metabolism by ubiquitinating and degrading complex II subunit succinate dehydrogenase complex subunit C (SDHC), leading to oxidative phosphorylation (OXPHOS) disability and aggravated TEC maladaptive repair. Preemptive and late depletion of Wwp2 both ameliorated unilateral ischemia-reperfusion (UIR) injury-induced AKI-to-CKD transition, and tubular-specific Wwp2 depletion resulted in the same protective phenotype. Furthermore, Sdhc knockdown abolished the protective effects of Wwp2 deletion in UIR mice. Conversely, SDHC overexpression attenuated OXPHOS impairment and TEC injury following WWP2 overexpression. Finally, we leveraged high-throughput virtual screening, enzyme activity assays, and binding affinity assays to identify two candidate WWP2 inhibitors. Both inhibitors significantly improved TEC maladaptive repair and deferred the AKI-to-CKD transition. Overall, we identified WWP2 as a critical regulator of mitochondrial OXPHOS integrity in maladaptive repairing TECs and identified two WWP2 inhibitors as potential drug candidates for interrupting the AKI-to-CKD transition. Show less
no PDF DOI: 10.1016/j.ymthe.2025.11.022
WWP2
Junjie Peng, Yichao Ou, Mingfeng Zhou +11 more · 2025 · Frontiers in pharmacology · Frontiers · added 2026-04-24
Hypothalamic obesity (HO) is a disabling disease caused by central nervous system (CNS) damage due to neurosurgery, trauma, or tumors, especially in hypothalamus. The pathological mechanism of its neu Show more
Hypothalamic obesity (HO) is a disabling disease caused by central nervous system (CNS) damage due to neurosurgery, trauma, or tumors, especially in hypothalamus. The pathological mechanism of its neural circuits is still unclear, and there is currently no corresponding drug due to the complex etiology. G protein-coupled receptors (GPCRs) regulate neural function in many CNS diseases. Among them, melanocortin 4 receptor (MC4R) regulate metabolism and appetite in the hypothalamus. Setmelanotide, an MC4R agonist, has demonstrated anti-obesity effects in genetic forms of obesity; however, its efficacy and mechanisms in HO remain unexplored. This study explored the potential of treating HO by setmelanotide-targeted activation of MC4R in the paraventricular nucleus (PVN). We established a rat hypothalamic injury model to replicate human HO symptoms, such as hyperphagia (50% increase in food intake), elevated Lee index, and more than 25% weight gain. Immunofluorescence and immunoblot analysis showed that HO disrupted the PVN neuropeptides, leading to the inhibition of MC4R via calmodulin-dependent protein kinase kinase 2 (CaMKK2) and AMP-activated protein kinase (AMPK) signaling. Crucially, administration of setmelanotide restored CaMKK2/AMPK activity, reactivated MC4R neurons, and normalized appetite and feeding behavior during fasting-refeeding and the long-term treatment of obese rats (60% reduction in food intake), ultimately reversing obesity (23% weight loss). These findings underscore the critical role of MC4R dysfunction in hypothalamic injury and highlight the strategies to pharmacologically activate MC4R via CaMKK2/AMPK signaling to restore metabolic homeostasis, proposing a translatable therapeutic agent to manage obesity caused by CNS injury. Show less
📄 PDF DOI: 10.3389/fphar.2025.1730786
MC4R
Shengyuan Wang, Zhongyang Wu, Zhe Zhong +2 more · 2025 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-24
Tissue acidification is a common feature of hypoxia, inflammation and solid tumor. Acidic pH regulates innate immune response in macrophages by weakening BRD4-containing transcriptional condensates. Y Show more
Tissue acidification is a common feature of hypoxia, inflammation and solid tumor. Acidic pH regulates innate immune response in macrophages by weakening BRD4-containing transcriptional condensates. Yet how disruption of transcriptional condensates leads to gene-specific regulation of immune programs remain unclear. Here, we integrated ATAC-seq, ChIP-seq, and RNA-seq of primary murine macrophages and performed integrative epigenomics analyses to identify transcriptional regulators (TRs) with pH-sensitive regulatory potential and association to BRD4-dependent transcriptional condensates. We determined pH-dependent super-enhancers (SEs) by extended profiles of BRD4 binding and h3K27ac marks. We found RELA, IRF family, and STAT family as candidate TRs enriched at BRD4-associated, pH-sensitive SE regions. RELA and IRF3 preferentially occupied BRD4-associated and pH-sensitive SEs, and displayed markedly reduced binding under acidic conditions, aligning with BRD4 occupancy change. Correspondingly, immune-response genes within BRD4-associated, pH-sensitive SE regions, including Show less
📄 PDF DOI: 10.1101/2025.10.29.685293
ACP2
Qingkai Song, Jiamei Wu, Qingfeng Zhang +9 more · 2025 · Molecular therapy. Methods & clinical development · Elsevier · added 2026-04-24
Systemic delivery of adeno-associated virus serotype 9 (AAV9) to the central nervous system (CNS) is insufficient due to hindrance from the tight junctions of the blood-brain barrier (BBB). While pept Show more
Systemic delivery of adeno-associated virus serotype 9 (AAV9) to the central nervous system (CNS) is insufficient due to hindrance from the tight junctions of the blood-brain barrier (BBB). While peptide-display-based AAV engineering has advanced CNS-targeting capsid development, traditional strategies inserting or substituting a 7-mer peptide remain limited by low success rates and scarcity of efficient variants. To address these issues, we developed the Multiple Capsid Mutation Strategies (MCMS) library, which enhanced sequence diversity by incorporating random peptide insertions flanked by AAV9 or variant-derived residues and peptide substitutions within the VR-VIII of the AAV9 capsid protein. Following capsid selection in mice, the leading AAV variant BRC06 was identified and validated across different mouse strains. BRC06 exhibited approximately 1.9-fold higher brain transgene expression than AAV.PHP.eB in C57BL/6J mice. In BALB/c mice, BRC06 achieved a 1,482-fold brain enhancement with a 92-fold liver reduction relative to AAV9. Sequence analysis revealed that BRC06 was derived from the MCMS library's substitution strategies. Additionally, host factor screening revealed AAVR-dependent entry with accessory factors like Show less
📄 PDF DOI: 10.1016/j.omtm.2025.101522
ACP2
Chunqing Li, Longting Wu, Fang Hu +2 more · 2025 · Ecology and evolution · Wiley · added 2026-04-24
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave ada Show more
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave adaptation by comparing brain transcriptomes of sympatric cave-dwelling ( Show less
📄 PDF DOI: 10.1002/ece3.72652
ADCY3
Zhimin Wu, Shuo Yan, Huimin Zhang +6 more · 2025 · International journal of molecular sciences · MDPI · added 2026-04-24
Cadmium (Cd) contamination in plants and soil poses significant risks to livestock, particularly sheep. Cd exposure often leads to severe gastrointestinal diseases in sheep that are difficult to treat Show more
Cadmium (Cd) contamination in plants and soil poses significant risks to livestock, particularly sheep. Cd exposure often leads to severe gastrointestinal diseases in sheep that are difficult to treat. Milk-derived exosomes, particularly those from sheep milk (SM-Exo), have shown potential in treating gastrointestinal disorders, though their efficacy in Cd-induced colitis remains unclear. In this study, we investigated the therapeutic potential of SM-Exo in a Cd-induced colitis model. Hu sheep were exposed to Cd, and their fecal microbiota were collected to prepare bacterial solutions for fecal microbiota transplantation (FMT) in mice. The changes in gut microbiota and gene expression were analyzed through microbiome and transcriptomics. Our results showed that prior to treatment, harmful bacteria (e.g., Show less
📄 PDF DOI: 10.3390/ijms26073299
ADCY3
Jing Wang, Haiyan Gu, Xiaorong Hu +2 more · 2025 · Journal of medical biochemistry · added 2026-04-24
This study examined the regulatory effects of Acceptance and Commitment Therapy (ACT) on T lymphocyte subsets, serum inflammatory cytokines, neurotrophic factors, antioxidant enzymes, and lipid peroxi Show more
This study examined the regulatory effects of Acceptance and Commitment Therapy (ACT) on T lymphocyte subsets, serum inflammatory cytokines, neurotrophic factors, antioxidant enzymes, and lipid peroxidation products in elderly cerebral stroke (CS) patients, providing insights into the multi-dimensional pathophysiological interactions and potential intervention strategies for chronic stroke recovery. In this randomized controlled trial, 120 elderly stroke patients were allocated to either an ACT group (ACT intervention; n = 60) or a routine group (conventional treatment; n = 60). Comprehensive assessments were performed to quantify: (1) peripheral T lymphocyte distribution (CD3+, CD4+, CD8+ subsets, and CD4+/CD8+ ratio), (2) serum inflammatory cytokines (IL-1p, IL-6, IL-10, and TNF-a), (3) neurotrophic factors (5-HT, NE, BDNF, and IGF-1), and (4) antioxidant enzymes (SOD, CAT) and lipid peroxidation products (MDA, NO) using flow cytometry, HPLC-ECD, and ELISA. Statistical analyses were conducted with SPSS 22.0. Following treatment, CS patients exhibited reduced CD3+ and CD4+ T-cell levels along with a decreased CD4+/CD8+ ratio, while CD8+ T-cell proportions were elevated (P< 0.05). Proinflammatory cytokine levels (IL-1 b, IL-6, and TNF-a) were significantly suppressed, whereas anti-inflammatory IL-10 expression increased (P < 0 .0 5 ). Notably, ACT demonstrated superior efficacy in restoring immune balance and attenuating inflammation compared to conventional intervention (P< 0.05). Furthermore, neurotrophic factors levels were elevated, and oxidative stress markers were ameliorated in CS after treatment (P< 0.05), suggesting that ACT enhances neurotrophic activity and mitigates oxidative injury. ACT likely confers neuroprotection through multi-target mechanisms, including modulation of T-cell subset homeostasis, upregulation of neurotrophic factors, and suppression of oxidative stress. Show less
📄 PDF DOI: 10.5937/jomb0-58244
BDNF
Zhuzhu Wu, Xiaolin Wang, Zitong Guan +6 more · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Inflammatory bowel disease (IBD) is a chronic, immune-mediated intestinal disorder driven by dysregulated immune responses in genetically susceptible individuals. Despite recent advances in treatment, Show more
Inflammatory bowel disease (IBD) is a chronic, immune-mediated intestinal disorder driven by dysregulated immune responses in genetically susceptible individuals. Despite recent advances in treatment, more than 30% of patients either fail to respond initially or lose response over time, underscoring the need for a deeper mechanistic understanding of immunogenetic pathways and the development of individualized therapeutic strategies. We first discuss how newly identified susceptibility genes (e.g., IL23R, NOD2, BDNF, SLC) and their polymorphisms influence immune cell function and epithelial barrier integrity. Single-cell technologies have further revealed novel cell subsets and interactions underlying disease heterogeneity. We then explore the clinical efficacy of classical and emerging targeted therapies, including cytokine-specific biologics, JAK inhibitors, and novel strategies aimed at restoring regulatory T-cell function or blocking integrin-mediated lymphocyte trafficking. Additionally, we highlight promising therapeutic approaches such as fecal microbiota transplantation, microbial metabolite-based interventions, and nanotherapeutics. We further discuss how genetic insights and immune biomarkers can facilitate treatment personalization and improve prognostic stratification. Ultimately, this review emphasizes the transition from broad immunosuppression to precision medicine and proposes integrated approaches-combining multiomics profiling, immune monitoring, and novel therapeutics-to achieve sustained remission and improve long-term outcomes in IBD patients. Show less
📄 PDF DOI: 10.3389/fimmu.2025.1719366
BDNF
Xiaona Li, Mei Lu, Xinkun Wang +6 more · 2025 · Frontiers in psychiatry · Frontiers · added 2026-04-24
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mecha Show more
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mechanisms and support future clinical trials. We searched PubMed, Embase, Web of Science, Cochrane Library, and OVID for studies on berberine in depression models up to March 20, 2025. Analysis used STATA 15.0 and Review Manager 5.4, with study quality assessed via SYRCLE's risk of bias tool. The meta-analysis included 18 studies (338animals). Overall, berberine significantly reduced depression-like behaviors in animal models.Specifically, BBR increased total locomotor activity in the open field test (SMD=2.79, 95% CI: 1.55, 4.02) and time spent in the center zone (SMD=2.49, 95% CI:1.61, 3.37), reduced immobility time in both the forced swim test and tail suspension test (SMD =-4.42, 95% CI:-5.77,-3.07; SMD=-4.46, 95% CI:-6.21, -2.71), increased sucrose intake in the sucrose preference test (SMD = 3.72, 95% CI: 2.37, 5.07), and reduced feeding latency in the novelty-suppressed feeding test (SMD=-5.72, 95% CI:-7.63, -3.82). However, BBR did not significantly alter the number of square crossings (SMD=1.36, 95%CI:-0.07 , 2.79) or rearing frequency (SMD=1.66, 95% CI: -0.29, 3.61) in the open field test. BBR also increased the levels of body weight, brain-derived neurotrophic factor, dopamine, serotonin, and norepinephrine,while reducing the levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Preclinical studies suggest that berberine may represent a promising therapeutic agent for the treatment of depressive disorders. Its antidepressant effects appear to be closely associated with the modulation of neurotransmitter levels,reduction of oxidative stress, and inhibition of inflammatory responses.However, methodological limitations may constrain these findings. Larger, more rigorous preclinical studies are needed for confirmation. https://inplasy.com/inplasy-2025-6-0002, identifier INPLASY202560002. Show less
📄 PDF DOI: 10.3389/fpsyt.2025.1653929
BDNF
Yingyi Wang, Haisu Wu, Ruijie Geng +4 more · 2025 · Alpha psychiatry · added 2026-04-24
To explore the molecular mechanisms underlying clozapine-induced metabolic syndrome (MetS) in schizophrenia patients, providing scientific evidence for clinicians to prevent and manage metabolic syndr Show more
To explore the molecular mechanisms underlying clozapine-induced metabolic syndrome (MetS) in schizophrenia patients, providing scientific evidence for clinicians to prevent and manage metabolic syndrome during the treatment of psychiatric disorders. Ten schizophrenia patients with MetS and ten matched controls were recruited from Shanghai Mental Health Center according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia and the 2016 Chinese Adult Dyslipidemia Prevention and Treatment Guidelines for MetS. Peripheral blood RNA sequencing was performed to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network were used to pinpoint hub genes. Mendelian randomization (MR) was conducted to validate causal relationship between serum brain-derived neurotrophic factor (BDNF) levels and MetS components. A total of 1019 DEGs were identified, grouped into eight mRNA modules through WGCNA. Key hub genes included Significant differences in gene expression are observed between schizophrenia patients with and without MetS. Individual variability in clozapine-induced MetS may be linked to DEGs. Show less
📄 PDF DOI: 10.31083/AP49352
BDNF
Yuxuan Song, Wenjing Pan, Linlin Meng +7 more · 2025 · Foods (Basel, Switzerland) · MDPI · added 2026-04-24
Cognitive impairment is acknowledged as an early stage between normal aging and Alzheimer's disease, emphasizing the need for prompt intervention. There is growing evidence that the gut-brain axis pla Show more
Cognitive impairment is acknowledged as an early stage between normal aging and Alzheimer's disease, emphasizing the need for prompt intervention. There is growing evidence that the gut-brain axis plays a role in regulating cognitive function, indicating that probiotics and their derivatives may impact cognitive functions through the brain-gut axis. In this study, we isolated and identified a novel bacterial strain Show less
📄 PDF DOI: 10.3390/foods14234037
BDNF
Yu Liu, Yansong Li, Ding Ding +7 more · 2025 · CNS neuroscience & therapeutics · Wiley · added 2026-04-24
Post-stroke cognitive impairment (PSCI) is a prevalent and disabling condition with limited effective treatment options. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a potential Show more
Post-stroke cognitive impairment (PSCI) is a prevalent and disabling condition with limited effective treatment options. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a potential non-invasive neuromodulation therapy. This review synthesizes recent advances in rTMS for PSCI, focusing on its mechanisms, therapeutic effects across cognitive domains, and safety profile. We summarize evidence indicating that rTMS exerts its effects by modulating cortical excitability, promoting neuroplasticity via BDNF signaling, and regulating dysfunctional brain networks, particularly the central executive and default mode networks. Clinical studies demonstrate that high-frequency stimulation, primarily targeting the dorsolateral prefrontal cortex (DLPFC), can significantly improve memory, executive function, attention, and activities of daily living (ADLs) in patients with PSCI. A favorable safety profile is reported, with mild and transient adverse effects being most common. However, significant heterogeneity in stimulation parameters (e.g., frequency, intensity, pulses) exists across studies. Current evidence suggests that ensuring a sufficient number of stimulation pulses and duration may be necessary. rTMS represents a promising therapeutic tool for PSCI, demonstrating benefits in key cognitive and functional domains. Future research must prioritize large-scale, standardized randomized controlled trials to optimize stimulation protocols, confirm long-term efficacy, and explore synergistic combinations with other rehabilitation strategies. Show less
📄 PDF DOI: 10.1002/cns.70702
BDNF
Xinyuan Qiu, Ruo-Ran Wang, Qing-Qian Wu +27 more · 2025 · The Journal of clinical investigation · added 2026-04-24
Impaired glucose-stimulated insulin secretion (GSIS) is a hallmark of β cell dysfunction in diabetes. Epigenetic mechanisms govern cellular glucose sensing and GSIS by β cells, but they remain incompl Show more
Impaired glucose-stimulated insulin secretion (GSIS) is a hallmark of β cell dysfunction in diabetes. Epigenetic mechanisms govern cellular glucose sensing and GSIS by β cells, but they remain incompletely defined. Here, we found that BAF60a functions as a chromatin regulator that sustains biphasic GSIS and preserves β cell function under metabolic stress conditions. BAF60a was downregulated in β cells from obese and diabetic mice, monkeys, and humans. β cell-specific inactivation of BAF60a in adult mice impaired GSIS, leading to hyperglycemia and glucose intolerance. Conversely, restoring BAF60a expression improved β cell function and systemic glucose homeostasis. Mechanistically, BAF60a physically interacted with Nkx6.1 to selectively modulate chromatin accessibility and transcriptional activity of target genes critical for GSIS coupling in islet β cells. A BAF60a V278M mutation associated with decreased β cell GSIS function was identified in human donors. Mice carrying this mutation, which disrupted the interaction between BAF60a and Nkx6.1, displayed β cell dysfunction and impaired glucose homeostasis. In addition, GLP-1R and GIPR expression was significantly reduced in BAF60a-deficient islets, attenuating the insulinotropic effect of GLP-1R agonists. Together, these findings support a role for BAF60a as a component of the epigenetic machinery that shapes the chromatin landscape in β cells critical for glucose sensing and insulin secretion. Show less
📄 PDF DOI: 10.1172/JCI177980
GIPR
Shu Wei Wong, Yong-Yu Yang, Hui Chen +4 more · 2025 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Metabolic dysfunction-associated steatotic liver disease (MASLD) covers a broad spectrum of profile from simple fatty liver, evolving to metabolic dysfunction-associated steatohepatitis (MASH), to hep Show more
Metabolic dysfunction-associated steatotic liver disease (MASLD) covers a broad spectrum of profile from simple fatty liver, evolving to metabolic dysfunction-associated steatohepatitis (MASH), to hepatic fibrosis, further progressing to cirrhosis and hepatocellular carcinoma (HCC). MASLD has become a prevalent disease with 25% in average over the world. MASH is an active stage, and requires pharmacological intervention when there is necroptotic damage with fibrotic progression. Although there is an increased understanding of MASH pathogenesis and newly approved resmetirom, given its complexity and heterogeneous pathophysiology, there is a strong necessity to develop more drug candidates with better therapeutic efficacy and well-tolerated safety profile. With an increased list of pharmaceutical candidates in the pipeline, it is anticipated to witness successful approval of more potential candidates in this fast-evolving field, thereby offering different categories of medications for selective patient populations. In this review, we update the advances in MASH pharmacotherapeutics that have completed phase II or III clinical trials with potential application in clinical practice during the latest 2 years, focusing on effectiveness and safety issues. The overview of fast-evolving status of pharmacotherapeutic candidates for MASH treatment confers deep insights into the key issues, such as molecular targets, endpoint selection and validation, clinical trial design and execution, interaction with drug administration authority, real-world data feedback and further adjustment in clinical application. Show less
no PDF DOI: 10.1038/s41401-024-01466-7
GIPR
Juan Du, Kaiyi Zhang, Jiakun Miao +6 more · 2025 · Life sciences · Elsevier · added 2026-04-24
This study aimed to explore the molecular pathological mechanisms of the liver in metabolic disease-susceptible transgenic pigs via multiomics analysis. The triple-transgenic (PNPLA3 The TG2 pigs pres Show more
This study aimed to explore the molecular pathological mechanisms of the liver in metabolic disease-susceptible transgenic pigs via multiomics analysis. The triple-transgenic (PNPLA3 The TG2 pigs presented mild metaflammation and insulin resistance (IR) which was similar to WT12 pigs. Compared with the other three groups, the TG12 pigs presented severe hepatocyte ballooning, fat deposition, and portal area fibrosis. The transcriptome data suggested that the TG2 pigs presented upregulated gene expression in the extracellular matrix (ECM). The TG12 pigs presented more severe metaflammation and exhibited imbalanced glycolipid metabolism. Interestingly, genes such as ETNPPL, GABBR2, and BMP8B might be key regulatory targets for liver injury. The metabolome and lipidome suggested that long-chain polyunsaturated fatty acids (LCPUFAs) and phospholipids with corresponding LCPUFAs were remodelled. Importantly, bis(monoacylglycerol) phosphates (BMPs) and sulfatides (SLs) could be the key regulatory metabolites in liver injury. ETNPPL, GABBR2, and BMP8B might be potential therapeutic targets for liver injury. BMPs and SLs might be biomarkers for the diagnosis and treatment of liver diseases. Show less
no PDF DOI: 10.1016/j.lfs.2024.123337
GIPR
Yanping Wang, Xiaoru Ma, Zhixin Qiao +16 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, bu Show more
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, but its astrocyte-related mechanisms remain unclear. Here, we demonstrated that EA at ST36 alleviated blood-brain barrier (BBB) disruption and neuroinflammation during the peak period of experimental autoimmune encephalomyelitis (EAE). Additionally, EA at ST36 upregulated the expression of α-melanocyte-stimulating hormone (α-MSH) and its receptor melanocortin-4 receptor (MC4R) in spinal astrocytes. Pharmacological studies showed that MC4R agonist RO27-3225 mimicked the therapeutic effects of EA, whereas MC4R antagonist TCMCB07 weakened EA-mediated BBB protection and neuroinflammation suppression. Moreover, astrocyte-specific silencing of MC4R via adeno-associated virus (AAV) weakened EA-mediated BBB protection and neuroinflammation suppression. RNA-sequencing (RNA-seq) and western blot (WB) revealed that EA exerts neuroprotective effects by activating MC4R to inhibit MAPK and NF-κB signaling pathways. Moreover, in MC4R-overexpressing astrocytes, α-MSH and RO27-3225 reduced inflammation responses, while TCMCB07 reversed the effects by MAPK/NF-κB signaling pathways. Collectively, our findings identify astrocytic MC4R as a critical mediator of EA-driven neuroprotection by suppressing MAPK/NF-κB signaling, providing mechanistic insight and a promising therapeutic target for EAE and other neuroinflammatory disorders. Show less
📄 PDF DOI: 10.1186/s12974-025-03667-1
MC4R
Y X Li, H X Peng, H D Guo +11 more · 2025 · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · added 2026-04-24
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases Show more
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases such as obesity. Several randomized controlled trials (RCTs) targeting obese or overweight populations have found that individuals with different genotypes exhibit varying responses to the same lifestyle intervention (gene-lifestyle intervention interactions). To date, more than 20 genes, including Show less
no PDF DOI: 10.3760/cma.j.cn112338-20250501-00297
MC4R
Todd Hulgan, Kristine M Erlandson, Yuki Bradford +11 more · 2025 · Open forum infectious diseases · Oxford University Press · added 2026-04-24
Given the melanocortin-4 receptor's (MC4R) importance in obesity, we examined associations between
📄 PDF DOI: 10.1093/ofid/ofaf696
MC4R
Peng Zhong, Chumeng Zhang, Qinfeng Wu +1 more · 2025 · Frontiers in genetics · Frontiers · added 2026-04-24
Cardiovascular diseases (CVDs), including myocardial infarction (MI), heart failure (HF), atrial fibrillation (AF), and arrhythmia, are major contributors to global mortality and often share overlappi Show more
Cardiovascular diseases (CVDs), including myocardial infarction (MI), heart failure (HF), atrial fibrillation (AF), and arrhythmia, are major contributors to global mortality and often share overlapping risk factors and pathophysiological mechanisms. While genome-wide association studies (GWAS) have identified many loci for individual CVDs, the shared genetic architecture across related traits-particularly in East Asian populations-remains underexplored. We integrated large-scale GWAS summary statistics from East Asian populations to perform genome-wide and local genetic correlation analyses across four CVD phenotypes and five cardiometabolic traits (blood pressure and lipid levels). Using stratified LD score regression, we assessed tissue-specific heritability enrichment. Multi-trait analysis of GWAS (MTAG) was then employed to identify pleiotropic loci associated with multiple traits, with functional annotation and expression quantitative trait loci (eQTL) data used to explore biological relevance. We observed extensive genetic correlations among CVDs and between CVDs and cardiometabolic traits, with HF showing the strongest connections to both MI and arrhythmia. Notable genome-wide correlations were found between MI and SBP (rg = 0.35, Our findings provide comprehensive insight into the shared genetic determinants of cardiovascular and metabolic diseases in East Asian populations. The identification of pleiotropic and ancestry-specific loci, along with tissue-specific regulatory patterns, underscores the need for integrative multi-trait and population-informed approaches in cardiovascular genetics and risk prediction. Show less
📄 PDF DOI: 10.3389/fgene.2025.1635378
MC4R
Haoxue Zhu, Xinghao Yi, Mengyu He +3 more · 2025 · Metabolism: clinical and experimental · Elsevier · added 2026-04-24
Dynamic interactions between genetic predispositions and environmental exposures significantly shape the escalating prevalence of childhood obesity. This systematic review synthesizes observational an Show more
Dynamic interactions between genetic predispositions and environmental exposures significantly shape the escalating prevalence of childhood obesity. This systematic review synthesizes observational and clinical trial evidence on the gene-environment interplays influencing childhood obesity, highlighting the role of genetic variants and environmental moderators such as dietary habits, physical activity, sleep durations, parental behaviors, socioeconomic status, ethnicity, gender, as well as lifestyle interventions. We conducted an exhaustive search across 5 databases (Medline, PubMed, EMBASE, Web of Science, and Cochrane Library), adhering to PRISMA guidelines. We ultimately included 147 studies that investigated these interplays in diverse populations. Specifically, 83 studies focused on gene-diet interplays, 23 on gene-physical activity, 5 on sedentary behavior, 3 on screen time, 7 on sleep duration, 10 on parental behavior, 4 on socioeconomic status, 16 on gender, 8 on age, 7 on ethnicity, and 13 on the effects of lifestyle interventions. Notably, we meta-analyzed energy expenditure and macronutrient consumption, including carbohydrates, proteins, and fats, as well as the proportion of energy supplied by each nutrient between carriers and noncarriers of the FTO effect allele, revealing that carriers consumed a higher proportion of fat calories, with no other significant differences noted. This review demonstrates that genetic risk variants, particularly in FTO (e.g., rs9939609) and MC4R (e.g., rs17782313), amplify the adverse effects of obesogenic behaviors, offering insights into the intricate pathophysiology of childhood obesity and suggesting the potential for personalized interventions based on genetic profiles. Show less
no PDF DOI: 10.1016/j.metabol.2025.156303
MC4R
Mateus R Amorim, Noah R Williams, O Aung +12 more · 2025 · The Journal of clinical investigation · added 2026-04-24
Weight loss medications are emerging candidates for pharmacotherapy of sleep-disordered breathing (SDB). A melanocortin 4 receptor (MC4R) agonist, setmelanotide (Set), is used to treat obesity caused Show more
Weight loss medications are emerging candidates for pharmacotherapy of sleep-disordered breathing (SDB). A melanocortin 4 receptor (MC4R) agonist, setmelanotide (Set), is used to treat obesity caused by abnormal melanocortin and leptin signaling. We hypothesized that Set can treat SDB in mice with diet-induced obesity. We performed a proof-of-concept randomized crossover trial of a single dose of Set versus vehicle and a 2-week daily Set versus vehicle trial, examined colocalization of Mc4r mRNAs with the markers of CO2-sensing neurons Phox2b and neuromedin B in the brainstem, and expressed Cre-dependent designer receptors exclusively activated by designer drugs (DREADDs) or caspase in obese Mc4r-Cre mice. Set increased minute ventilation across sleep/wake states, enhanced the hypercapnic ventilatory response (HCVR), and abolished apneas during sleep. Phox2b+ neurons in the nucleus of the solitary tract (NTS) and the parafacial region expressed Mc4r. Chemogenetic stimulation of the MC4R+ neurons in the parafacial region, but not in the NTS, augmented HCVR without any changes in metabolism. Caspase elimination of the parafacial MC4R+ neurons abolished effects of Set on HCVR. Parafacial MC4R+ neurons projected to the respiratory premotor neurons retrogradely labeled from C3-C4. In conclusion, MC4R agonists enhance the HCVR and treat SDB by acting on the parafacial MC4R+ neurons. Show less
📄 PDF DOI: 10.1172/JCI177823
MC4R
Lin Ai, Yi Han, Ting Ge +14 more · 2025 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Some individuals are more susceptible to developing or suffering from pain states than others. However, the brain mechanisms underlying the susceptibility to pain responses are unknown. In this study, Show more
Some individuals are more susceptible to developing or suffering from pain states than others. However, the brain mechanisms underlying the susceptibility to pain responses are unknown. In this study, we defined pain susceptibility by recapitulating inter-individual differences in pain responses in mice exposed to a paradigm of socially transferred allodynia (STA), and with a combination of chemogenetic, molecular, pharmacological and electrophysiological approaches, we identified GABA-ergic neurons in the dorsal raphe nucleus (DRN) as a cellular target for the development and maintenance of STA susceptibility. We showed that DRN GABA-ergic neurons were selectively activated in STA-susceptible mice when compared with the unsusceptible (resilient) or control mice. Chemogenetic activation of DRN GABA-ergic neurons promoted STA susceptibility; whereas inhibiting these neurons prevented the development of STA susceptibility and reversed established STA. In in vitro slice electrophysiological analysis, we demonstrated that melanocortin 4 receptor (MC4R) enriched in DRN GABA-ergic neurons was a molecular target for regulating pain susceptibility, possibly by affecting DRN GABA-ergic neuronal activity. These results establish the DRN GABA-ergic neurons as an essential target for controlling pain susceptibility, thus providing important information for developing conceptually innovative and more accurate analgesic strategies. Show less
no PDF DOI: 10.1038/s41401-025-01494-x
MC4R
Zhihao Wang, Zhengsheng Wu · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Lung squamous cell carcinoma (LUSC) is a leading cause of cancer-related mortality. Although immunotherapy has recently demonstrated clinical benefits, the biological roles of immune-related genes (IR Show more
Lung squamous cell carcinoma (LUSC) is a leading cause of cancer-related mortality. Although immunotherapy has recently demonstrated clinical benefits, the biological roles of immune-related genes (IRGs) in LUSC remain insufficiently understood. In this study, transcriptomic and clinical data from 493 LUSC patients were obtained from The Cancer Genome Atlas (TCGA). IRGs were identified through weighted gene co-expression network analysis, followed by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regression to screen for prognostic genes and establish a risk prediction model. The model's predictive performance was validated, and the immune landscape associated with distinct risk subgroups was systematically characterized. Expression patterns and clinical significance of the signature genes were further investigated using bioinformatics analysis, quantitative real-time PCR, Western blotting, and immunohistochemistry. A total of 55 differentially expressed IRGs were identified, among which 8 genes ( This study establishes a novel IRGs-based prognostic signature with potential utility for risk stratification and individualized immunotherapeutic strategies in LUSC. Furthermore, it also provides valuable insights into the role of Show less
📄 PDF DOI: 10.3389/fimmu.2025.1724319
ANGPTL4
Anyu Zeng, Hongmin Chen, Tianqi Luo +13 more · 2025 · Molecular cancer · BioMed Central · added 2026-04-24
Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CA Show more
Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CAFs) contribute to immunosuppression in osteosarcoma are not fully understood. We performed single-cell RNA sequencing (scRNA-seq) on osteosarcoma tissues from patients treated with neoadjuvant chemotherapy and anti-PD-1 therapy to investigate the tumor microenvironment. Cellular composition, gene expression programs, and signaling pathways were analyzed. Functional assays, pull-down and PLA-flow binding validation, and in vivo mouse models were used to dissect the mechanisms by which CAF-derived factors influence CD8⁺ T cell function and contribute to immunotherapy response. We identified a subpopulation of CD36⁺ CAFs, characterized by adaptive uptake of oxidized low-density lipoprotein (OxLDL) and activation of the PPARG-FABP4 axis. This metabolic program promoted ANGPTL4 secretion, which bound integrin on CD8⁺ T cells and activated the JAK2-STAT3 pathway, leading to T cell exhaustion and impaired effector function. In vivo, administration of VitE effectively scavenged OxLDL, reprogrammed the TME, enhanced CD8⁺ T cell infiltration, and synergized with PD-1 blockade to improve tumor control. CD36⁺ CAFs drive immunosuppressive metabolic reprogramming via the OxLDL-PPARG-ANGPTL4 axis, promoting CD8⁺ T cell exhaustion and resistance to immunotherapy in osteosarcoma. Targeting this pathway with VitE alleviated CAF-mediated immune suppression and enhanced PD-1 blockade responses in preclinical models, providing a rationale for metabolism-based combinatorial strategies in osteosarcoma. Show less
📄 PDF DOI: 10.1186/s12943-025-02516-2
ANGPTL4
Ning Ding, Meimei Jiang, Guiyun Jia +6 more · 2025 · Computers in biology and medicine · Elsevier · added 2026-04-24
The heterogeneity of the tumor immune microenvironment (TIME) and therapeutic resistance in Colorectal cancer (CRC) present substantial clinical challenges. In this study, 1136 CRC samples from TCGA a Show more
The heterogeneity of the tumor immune microenvironment (TIME) and therapeutic resistance in Colorectal cancer (CRC) present substantial clinical challenges. In this study, 1136 CRC samples from TCGA and GEO were utilized for the overall research design, and tumor subtype classification (Immunity_High and Immunity_Low) was specifically performed on the TCGA cohort (n = 568) using single-sample gene set enrichment analysis (ssGSEA) and t-SNE dimensionality reduction; t-SNE was selected because the study focused on distinguishing local clustering features of immune subtypes-it excels in enhancing sample aggregation within subtypes and highlighting local differences, which aligns with classification needs, so UMAP (prioritizing global structure preservation) was not used. The GEO cohort (n = 568) was used for subsequent validation of the prognostic model and results. A 12-gene prognostic model, comprising ANGPTL4, FABP4, RBP7, and 9 additional non-core genes (CCL22, NOS2, TGFB3, APOD, CHGB, CX3CL1, APOBEC3F, LCN12, BST2), was developed using Least Absolute Shrinkage and Selection Operator-Cox regression (LASSO-Cox regression) regression.The functions of the core genes and potential therapeutic candidates were investigated via single-cell sequencing, molecular docking, dynamics simulations, drug sensitivity analysis, Human Protein Atlas (HPA) and quantitative Real - time Polymerase Chain Reaction (qPCR). The Immunity_High subtype, characterized by the presence of CD8 This multi-omics study integrates multi-omics data to elucidate the immune-metabolic heterogeneity in CRC, establishing a precise prognostic model and providing bioinformatic evidence for key roles of ANGPTL4, FABP4, and RBP7 in the tumor microenvironment, thereby suggesting novel strategies to overcome immunotherapy resistance. Show less
no PDF DOI: 10.1016/j.compbiomed.2025.111271
ANGPTL4
Meng-Wei Lin, Chung-Hao Li, Hung-Tsung Wu +4 more · 2025 · Journal of clinical medicine · MDPI · added 2026-04-24
📄 PDF DOI: 10.3390/jcm14217599
ANGPTL4
Wenxue Yao, Qianqian Sun, Ruize Wu +7 more · 2025 · Environmental pollution (Barking, Essex : 1987) · Elsevier · added 2026-04-24
Nickel exposure increases the risk of lung cancer; however, the mechanisms underlying nickel-induced oncogenic cell death remain unclear. While ferroptosis is linked to lung cancer, its role in nickel Show more
Nickel exposure increases the risk of lung cancer; however, the mechanisms underlying nickel-induced oncogenic cell death remain unclear. While ferroptosis is linked to lung cancer, its role in nickel-induced malignant transformation is not well understood. We simulated long-term exposure of human bronchial epithelial cells (Beas-2B cells) to nickel-refining fumes (NiRF) from a smelter and found that NiRF exposure induced their malignant transformation. Ferroptosis was inhibited in these transformed cells (2B-NiRF cells), a phenomenon also observed in NiRF-exposed mouse lung tissue. Treatment of 2B-NiRF cells with ferroptosis inducers and inhibitors indicated that ferroptosis suppresses their malignant phenotype. Transcriptome analysis of 2B-NiRF cells revealed enrichment in hypoxia and HIF-1 signaling pathways. Mechanistically, the NiRF-induced hypoxic microenvironment inactivates prolyl hydroxylase domain protein 1 (PHD1), stabilizing hypoxia-inducible factor-1α (HIF-1α), which coordinates the transcriptional program to maintain 2B-NiRF cells in a ferroptosis-resistant state. Overexpression of PHD1 inhibits HIF-1α and its downstream angiopoietin-like protein 4 (ANGPTL4)/janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, thereby restoring sensitivity to ferroptosis in 2B-NiRF cells; knockdown of ANGPTL4 similarly modulates sensitivity to ferroptosis. This underscores the crucial role of the PHD1/HIF-1α/ANGPTL4/JAK2/STAT3 axis in ferroptosis-mediated NiRF-induced malignant transformation. The NiRF-exposed mouse model further confirms that in vivo expression of the PHD1/HIF-1α/ANGPTL4/JAK2/STAT3 axis is dysregulated. In conclusion, this study reveals a novel regulatory cascade in which NiRF inhibits cellular ferroptosis via the PHD1/HIF-1α/ANGPTL4/JAK2/STAT3 axis, thereby inducing malignant transformation of cells, providing potential targets for occupational lung cancer risk management against ferroptosis. Show less
no PDF DOI: 10.1016/j.envpol.2025.127205
ANGPTL4
Ze Wu, Lanlan Fang, Xuan Dang +5 more · 2025 · Reproduction (Cambridge, England) · added 2026-04-24
How extravillous trophoblast (EVT) invasion is regulated during placental development remains an important question in reproductive biology. This study demonstrates that growth differentiation factor- Show more
How extravillous trophoblast (EVT) invasion is regulated during placental development remains an important question in reproductive biology. This study demonstrates that growth differentiation factor-11 (GDF-11) promotes EVT invasion by upregulating angiopoietin-like 4 (ANGPTL4) via ALK4/ALK5-SMAD3 signaling, revealing a novel mechanism in placental biology. Proper regulation of extravillous trophoblast (EVT) cell invasion is critical for normal placental development and function. Growth differentiation factor 11 (GDF-11), a member of the transforming growth factor-β (TGF-β) superfamily, has been shown to promote EVT cell invasion, yet the underlying molecular mechanisms remain largely unclear. In this study, RNA sequencing identified angiopoietin-like 4 (ANGPTL4), a multifunctional secreted protein, as a novel downstream target of GDF-11. In vitro experiments demonstrated that GDF-11 significantly upregulated ANGPTL4 expression in both HTR-8/SVneo cells and primary human EVT cells. Mechanistically, we found that the type I TGF-β receptors ALK4 and ALK5 were essential for mediating the stimulatory effect of GDF-11 on ANGPTL4 expression. Further analysis revealed that SMAD3, but not SMAD2, was the key transcription factor involved in this process. Using both loss- and gain-of-function approaches, we demonstrated that ANGPTL4 was required for GDF-11-induced EVT cell invasion. Importantly, serum levels of GDF-11 were markedly reduced in patients with preeclampsia (PE), a pregnancy disorder associated with shallow trophoblast invasion and poor placentation. Together, our findings uncover a previously unrecognized GDF-11-ANGPTL4 signaling axis that regulates EVT cell invasion and provides new insight into the pathophysiology of PE. Show less
no PDF DOI: 10.1530/REP-25-0244
ANGPTL4